|
π
|
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
15 auth.
A. Bellacosa,
D. de Feo,
A. Godwin,
D. Bell,
J. Cheng,
D. Altomare,
M. Wan,
L. Dubeau,
G. Scambia,
V. Masciullo,
...
G. Ferrandina,
P. Panici,
S. Mancuso,
G. Neri,
J. Testa
|
9 |
1995 |
9
π
|
|
π
|
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
30 auth.
S. Pignata,
G. Scambia,
D. Katsaros,
C. Gallo,
E. Pujade-Lauraine,
S. De Placido,
A. Bologna,
B. Weber,
F. Raspagliesi,
P. Panici,
G. Cormio,
R. Sorio,
M. Cavazzini,
G. Ferrandina,
E. Breda,
...
V. Murgia,
C. Sacco,
S. Cinieri,
V. Salutari,
C. Ricci,
C. Pisano,
S. Greggi,
R. Lauria,
D. Lorusso,
C. Marchetti,
L. Selvaggi,
S. Signoriello,
M. Piccirillo,
M. Di Maio,
F. Perrone
|
8 |
2014 |
8
π
|
|
π
|
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
12 auth.
A. Fagotti,
G. Ferrandina,
G. Vizzielli,
F. Fanfani,
V. Gallotta,
V. Chiantera,
...
B. Costantini,
P. Margariti,
S. Gueli Alletti,
F. Cosentino,
L. Tortorella,
G. Scambia
|
8 |
2016 |
8
π
|
|
π
|
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
11 auth.
S. Mozzetti,
C. Ferlini,
P. Concolino,
Flavia Filippetti,
G. Raspaglio,
S. Prislei,
...
D. Gallo,
E. Martinelli,
F. Ranelletti,
G. Ferrandina,
G. Scambia
|
8 |
2005 |
8
π
|
|
π
|
A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study
7 auth.
A. Fagotti,
G. Ferrandina,
F. Fanfani,
A. Ercoli,
D. Lorusso,
Marco Rossi,
...
G. Scambia
|
8 |
2006 |
8
π
|
|
π
|
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
8 auth.
A. Fagotti,
G. Ferrandina,
F. Fanfani,
G. Garganese,
G. Vizzielli,
V. Carone,
...
M. Salerno,
G. Scambia
|
8 |
2008 |
8
π
|
|
π¦
|
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
11 auth.
G. Ferrandina,
M. Ludovisi,
D. Lorusso,
S. Pignata,
E. Breda,
A. Savarese,
...
P. del Medico,
L. Scaltriti,
D. Katsaros,
D. Priolo,
G. Scambia
|
8 |
2008 |
8
π¦
|
|
π
|
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.
10 auth.
M. Maurizi,
G. Almadori,
G. Ferrandina,
M. Distefano,
ME Romanini,
G. Cadoni,
...
P. BenedettiβPanici,
Gaetano Paludetti,
G. Scambia,
S. Mancuso
|
7 |
1996 |
7
π
|
|
π¦
|
Expression of CD133-1 and CD133-2 in ovarian cancer
13 auth.
G. Ferrandina,
G. Bonanno,
L. Pierelli,
A. Perillo,
A. Procoli,
A. Mariotti,
Maria Corallo,
E. Martinelli,
S. Rutella,
A. Paglia,
...
G. Zannoni,
S. Mancuso,
G. Scambia
|
7 |
2007 |
7
π¦
|
|
π
|
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target
11 auth.
G. Scambia,
F. Ranelletti,
P. Panici,
R. Vincenzo,
G. Bonanno,
G. Ferrandina,
...
M. Piantelli,
S. Bussa,
C. Rumi,
M. Cianfriglia,
S. Mancuso
|
7 |
2004 |
7
π
|
|
π
|
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
30 auth.
S. Pignata,
G. Scambia,
G. Ferrandina,
A. Savarese,
R. Sorio,
E. Breda,
V. Gebbia,
P. Musso,
L. Frigerio,
P. del Medico,
A. Lombardi,
A. Febbraro,
P. Scollo,
A. Ferro,
S. Tamberi,
...
A. Brandes,
A. Ravaioli,
M. Valerio,
E. Aitini,
D. Natale,
L. Scaltriti,
S. Greggi,
C. Pisano,
D. Lorusso,
V. Salutari,
F. Legge,
M. Di Maio,
A. Morabito,
C. Gallo,
F. Perrone
|
7 |
2011 |
7
π
|
|
π¦
|
Class III Ξ²-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients
8 auth.
G. Ferrandina,
G. Zannoni,
E. Martinelli,
A. Paglia,
V. Gallotta,
S. Mozzetti,
...
G. Scambia,
C. Ferlini
|
7 |
2006 |
7
π¦
|
